International Hepatitis Interventional Therapy Group

International Hepatitis Interventional Therapy Group is a biotechnology company focused on the development of therapeutic interventions for chronic viral hepatitis. The company's flagship program is the YIC vaccine, a yeast-derived hepatitis B surface antigen-antibody complex designed to induce immune clearance of the virus in chronic carriers. Developed in collaboration with researchers from Fudan University, the YIC vaccine underwent extensive Phase II and Phase III clinical testing in China. The group represents a significant effort in the field of immunotherapy for infectious diseases, specifically targeting the high burden of Hepatitis B in the Asian-Pacific region. Although the primary clinical trials for YIC concluded with mixed results regarding long-term efficacy, the company remains a notable entity in the history of Chinese biotech innovation. The company has historically operated as a specialized vehicle for the commercialization of academic research into clinical-grade therapeutics.